New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test.

Read more on PR Newswire via Yahoo! Finance